Free US stock insider buying and selling tracking with regulatory filing analysis for inside information on company health. We monitor corporate insider transactions because company officers often have the best understanding of their business prospects.
ProQR Therapeutics N.V. Ordinary Shares (PRQR), a clinical-stage biotech firm focused on RNA-based therapies for rare genetic diseases, is trading at $1.82 as of April 6, 2026, marking a 6.55% gain in recent trading. This analysis evaluates current price action, sector context, key technical support and resistance levels, and potential near-term scenarios for the stock, with no recent earnings data available for the company as of this publication. The recent upward move comes amid mixed sentimen
Is ProQR (PRQR) Stock Good for Short Term | Price at $1.82, Up 6.55% - Take Profit Levels
PRQR - Stock Analysis
3112 Comments
1891 Likes
1
Alixandrea
Registered User
2 hours ago
Highlights the importance of volume and momentum nicely.
👍 158
Reply
2
Zelaia
Consistent User
5 hours ago
Missed the chance… again. 😓
👍 112
Reply
3
Teandre
Regular Reader
1 day ago
Great summary of current market conditions!
👍 35
Reply
4
Casidhe
Daily Reader
1 day ago
Wish I had seen this pop up earlier.
👍 268
Reply
5
Vesenia
Insight Reader
2 days ago
The market is showing mixed signals today, with investors keeping a close eye on both domestic and global news.
👍 203
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.